Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China

OBJECTIVE: Results of CameL-sq has revealed the clinical benefits to patients with advanced squamous non-small-cell lung cancer (sq-NSCLC). This study aims to evaluate the cost-effectiveness of camrelizumab plus chemotherapy to treat sq-NSCLC from the perspective of the Chinese healthcare system. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Taihang, Ren, Yinan, Zhao, Mingye, Tang, Wenxi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423383/
https://www.ncbi.nlm.nih.gov/pubmed/36045725
http://dx.doi.org/10.3389/fpubh.2022.912921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423383/
https://www.ncbi.nlm.nih.gov/pubmed/36045725
http://dx.doi.org/10.3389/fpubh.2022.912921

Ejemplares similares